LLY Eli Lilly and Company Loading...

From BIIB earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
12:00
Apr 29 ◎
Alicia Alimo President of North America, Biogen Inc. BIIB Q1 FY26 call
CMS has added blood-based biomarkers as a reimbursable confirmation test for Leqembi, addressing a major physician hesitation. — This policy change lowers a barrier to Leqembi adoption, potentially accelerating its uptake and increasing competitive pressure on Eli Lilly's Kisunla.
LLY
HIGH

About LLY Analyst Coverage

Buzzberg tracks LLY (Eli Lilly and Company) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Alicia Alimo.